U.S. To Assign 15 FDA Inspectors To China In October
This article was originally published in PharmAsia News
Executive Summary
The U.S. government plans to assign as many as 15 inspectors to three major cities in China, beginning in October, to conduct U.S. FDA inspections of drug and other regulated products. In an interview, Michael Leavitt, secretary of Health and Human Services, said China still has not solved all the problems it had with safety of items made for export to the United States, but "they moved aggressively to begin making progress." The first inspectors are to be placed in Beijing, Shanghai and Guangzhou, Leavitt said, but added he does not expect many future problems with Chinese-made drugs and other products. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.